AR119317A1 - Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 - Google Patents

Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1

Info

Publication number
AR119317A1
AR119317A1 ARP200101852A ARP200101852A AR119317A1 AR 119317 A1 AR119317 A1 AR 119317A1 AR P200101852 A ARP200101852 A AR P200101852A AR P200101852 A ARP200101852 A AR P200101852A AR 119317 A1 AR119317 A1 AR 119317A1
Authority
AR
Argentina
Prior art keywords
positive
allesteric
modulator
tetrahydroisoquinoline derivative
substituted tetrahydroisoquinoline
Prior art date
Application number
ARP200101852A
Other languages
English (en)
Spanish (es)
Inventor
Anne Valade
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AR119317A1 publication Critical patent/AR119317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP200101852A 2019-07-01 2020-06-30 Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 AR119317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01

Publications (1)

Publication Number Publication Date
AR119317A1 true AR119317A1 (es) 2021-12-09

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101852A AR119317A1 (es) 2019-07-01 2020-06-30 Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1

Country Status (28)

Country Link
US (1) US12358890B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993795B1 (cg-RX-API-DMAC7.html)
JP (1) JP7618597B2 (cg-RX-API-DMAC7.html)
KR (1) KR102949226B1 (cg-RX-API-DMAC7.html)
CN (1) CN114008032B (cg-RX-API-DMAC7.html)
AR (1) AR119317A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020299705B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139622A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002949A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017740A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22007557A (cg-RX-API-DMAC7.html)
ES (1) ES3069145T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260599T1 (cg-RX-API-DMAC7.html)
IL (1) IL289317B2 (cg-RX-API-DMAC7.html)
MA (1) MA56445B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021015872A (cg-RX-API-DMAC7.html)
MY (1) MY210362A (cg-RX-API-DMAC7.html)
PE (1) PE20220373A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552819A1 (cg-RX-API-DMAC7.html)
PL (1) PL3993795T3 (cg-RX-API-DMAC7.html)
RS (1) RS68243B1 (cg-RX-API-DMAC7.html)
SA (1) SA521431274B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112539XA (cg-RX-API-DMAC7.html)
TW (1) TWI842923B (cg-RX-API-DMAC7.html)
UA (1) UA130613C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021001286A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109194B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520217A (ja) 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EA035544B1 (ru) 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
EP3596060B1 (en) * 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
BR112021022379A2 (pt) 2022-03-08
AU2020299705B2 (en) 2026-03-19
US12358890B2 (en) 2025-07-15
CN114008032B (zh) 2023-11-10
AU2020299705A1 (en) 2021-12-09
IL289317B2 (en) 2025-09-01
SA521431274B1 (ar) 2024-01-09
US20220251064A1 (en) 2022-08-11
CO2021017740A2 (es) 2022-01-17
IL289317A (en) 2022-02-01
JP7618597B2 (ja) 2025-01-21
KR20220029687A (ko) 2022-03-08
MX2021015872A (es) 2022-02-03
EP3993795A1 (en) 2022-05-11
TW202115009A (zh) 2021-04-16
SG11202112539XA (en) 2021-12-30
IL289317B1 (en) 2025-05-01
TWI842923B (zh) 2024-05-21
ZA202109194B (en) 2023-11-29
KR102949226B1 (ko) 2026-04-06
CA3139622A1 (en) 2021-01-07
PE20220373A1 (es) 2022-03-16
MA56445B1 (fr) 2026-05-26
ECSP22007557A (es) 2022-02-25
PH12021552819A1 (en) 2022-09-28
CL2021002949A1 (es) 2022-07-15
HRP20260599T1 (hr) 2026-06-05
CN114008032A (zh) 2022-02-01
MA56445A (fr) 2022-05-11
UA130613C2 (uk) 2026-04-01
MY210362A (en) 2025-09-13
PL3993795T3 (pl) 2026-07-20
EP3993795C0 (en) 2026-04-22
EP3993795B1 (en) 2026-04-22
WO2021001286A1 (en) 2021-01-07
ES3069145T3 (en) 2026-06-04
RS68243B1 (en) 2026-07-31
JP2022537994A (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2023003989A (es) Compuestos, composiciones y metodos.
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CO2021014210A2 (es) Compuestos de pirrol
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
ECSP22007557A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CO2021017202A2 (es) Compuestos tricíclicos
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
ECSP23041779A (es) Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1
CO2019015086A2 (es) Moduladores de tetrahidropiridopirazina de gpr6
AR111416A2 (es) Compuesto terapéutico para el dolor y síntesis del compuesto
AR113817A1 (es) Compuestos útiles para inhibir a cdk7